Merck & Co is deepening its bet on artificial intelligence with a long-term partnership with Google Cloud, committing up to $1 billion over several years to expand its AI infrastructure, talent base, and access to advanced models, including the Gemini Enterprise platform.
The agreement, unveiled at Google Cloud Next, formalizes an existing collaboration and signals a shift from experimentation to large-scale deployment across the pharmaceutical value chain. Executives from both companies said the partnership will embed Google engineers within Merck’s operations, effectively integrating external AI capabilities into core research, regulatory, and commercial workflows.
“I easily see us investing a billion over the next several years in this, in those capabilities,” said Dave Williams. “We’re not just buying tokens. It is really the tool set” Google Cloud offers, he added, pointing to the combination of Gemini Enterprise, engineering support, and underlying infrastructure.
Register for Tekedia Mini-MBA edition 20 (June 8 – Sept 5, 2026).
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab.
The scope of the collaboration is unusually broad. Rather than focusing on a single use case, the companies plan to deploy AI across drug discovery, clinical development, regulatory submissions, manufacturing optimization, and commercial operations. That breadth reflects a growing industry view that AI’s impact in pharmaceuticals will be cumulative, driven by incremental efficiency gains at each stage rather than a single breakthrough application.
Williams indicated the partnership is likely to run for at least a decade, underscoring both the scale of the investment and the complexity of integrating AI into highly regulated scientific workflows. The absence of a fixed timeline suggests the companies are prioritizing iterative deployment over rigid milestones, a common approach in large-scale digital transformation programmes.
The deal strengthens Google Cloud’s position in a high-value vertical where data intensity, regulatory complexity, and compute demands create barriers to entry. Alphabet Inc. has been pushing aggressively to position its AI stack, particularly Gemini Enterprise, as enterprise-grade infrastructure capable of handling sensitive workloads in sectors such as healthcare and finance.
“We’ve always said we wanted AI to play a positive role in society. One of the ways is to help people find cures to illnesses,” said Thomas Kurian. “They have the domain knowledge. We’re bringing the AI tools and platform and cyber capability to help them build using these tools.”
At the operational level, Merck is targeting measurable efficiency gains. Williams said AI will be used to run computerized simulations of laboratory experiments, reducing reliance on time-consuming physical trials in early-stage research. The company also plans to expand its use of AI in regulatory processes, an area where documentation requirements are extensive and often repetitive.
Merck has already been applying AI to prepare sections of clinical study reports for about two years, with what Williams described as positive results. The next phase involves scaling that capability across a wider set of documents and jurisdictions, turning isolated productivity gains into system-wide efficiencies.
“We feel there’s a tremendous opportunity there, and it’s a huge information challenge,” he said.
One of the more immediate impacts has been on market access. Williams said the company has used Google’s technology to cut by half the time and cost required to compile regulatory dossiers — detailed submissions needed in many countries to secure reimbursement approval for new medicines.
“This isn’t a pilot,” he said. “We’re submitting dossiers in markets using this new capability, and we’re now scaling it globally.”
That transition from pilot to production is remarkable. Many pharmaceutical companies have experimented with AI in limited settings, but fewer have moved to full-scale deployment tied to core business outcomes such as regulatory approval timelines and revenue realization.
The logic is that drug development remains one of the most expensive and time-intensive processes in modern industry, often taking more than a decade and billions of dollars to bring a single therapy to market. Even marginal reductions in time-to-approval can translate into substantial financial gains, while also accelerating patient access to treatments.
But the partnership is seen as a reflection of a broader shift in how pharmaceutical companies are approaching technology. Firms are increasingly forming deep alliances with cloud providers, effectively outsourcing parts of their digital infrastructure while retaining control over proprietary data and scientific expertise.
The Merck–Google Cloud collaboration sits within a wider competitive landscape, where major technology firms are racing to secure long-term contracts with healthcare companies as AI adoption accelerates. These partnerships are becoming foundational, shaping not only operational efficiency but also the pace and direction of innovation in drug discovery.
What distinguishes this deal is its scale and integration. By committing up to $1 billion and embedding external engineers within its teams, Merck is treating AI not as an auxiliary tool but as core infrastructure — a shift that could redefine how pharmaceutical research and development is conducted over the next decade.
The model, if successful, is expected to compress development timelines, streamline regulatory pathways, and lower operational costs. But it also raises execution risks, particularly around data governance, regulatory compliance, and the challenge of aligning advanced AI systems with the rigorous standards required in clinical science.